Common antibiotics pose a rare risk of severe liver injury in older patients

August 13, 2012

The commonly used broad-spectrum antibiotics moxifloxacin and levofloxacin are associated with an increased risk of severe liver injury in older people, according to a new study published in CMAJ (Canadian Medical Association Journal).

Moxifloxacin and levofloxacin are commonly prescribed "fluoroquinolone" often used for bacterial infections such as respiratory infections, and others. However, both the European Medicines Agency and Health Canada have issued warnings about the risk of liver injury from moxifloxacin, although there are few published studies on the safety of fluoroquinolones, especially related to .

Researchers from the Institute for Clinical Evaluative Sciences (ICES), Toronto; the University of Toronto and McMaster University, Hamilton, Ont., examined the risk of acute liver injury in patients taking moxifloxacin compared with those taking other antibiotics commonly used to treat . They looked at 9 years of data from Ontario to identify people aged 66 years or older with no history of liver disease who were admitted to hospital for liver injury within 30 days after receiving a prescription for these antibiotics. Excluding patients admitted for previous or recent hospitalization, 144 patients were admitted for acute liver injury, with the median time from the dispensing of the antibiotic to admission to hospital being 9 days. Eighty-eight (61.1%) of patients died during their index admission to hospital for liver injury.

"Compared with clarithromycin, moxifloxacin was associated with a more than 2-fold increased risk of admission to hospital for acute liver injury," writes Dr. David Juurlink, ICES, with coauthors. "Levofloxacin was also associated with a statistically significant but lower risk of hepatotoxicity than…moxifloxacin."

The authors note that, although these cases are serious, they are relatively rare, with about 6 cases for every 100 000 patients treated with the antibiotics.

The authors believe their findings are an important contribution to the evidence regarding the risks of these antibiotics. "Despite recent regulatory warnings regarding the hepatic safety of moxifloxacin, there is a lack of controlled studies supporting the notion that moxifloxacin presents a particular risk relative to other broad-spectrum antibiotic agents and, in particular, to other fluoroquinolones," write the authors.

They conclude: "Although our results require confirmation in other settings, the findings suggest that both moxifloxacin and levofloxacin be considered for regulatory warnings regarding acute ."

Explore further: Combination antibiotic treatment does not result in less organ failure in adults with severe sepsis

More information: Paper online: www.cmaj.ca/lookup/doi/10.1503/cmaj.111823

Related Stories

Combination antibiotic treatment does not result in less organ failure in adults with severe sepsis

May 21, 2012
Frank M. Brunkhorst, M.D., of Friedrich-Schiller University, Jena, Germany, and colleagues conducted a study to compare the effect of the antibiotics moxifloxacin and meropenem with the effect of meropenem monotherapy on ...

Body building, diet supplements linked to liver damage: study

May 22, 2012
(HealthDay) -- Body-building and weight-loss products are the types of dietary supplements most likely to cause liver injury, according to a small new study.

3-fold increase in acute dialysis after cardiac, vascular surgeries

June 25, 2012
There has been a three-fold increase in the number of patients receiving acute dialysis because of injury after cardiac and vascular surgeries since 1995, states a new study in CMAJ (Canadian Medical Association Journal).

Recommended for you

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

Non-psychotropic cannabinoids show promise for pain relief

September 4, 2017
Some cancers love bone. They thrive in its nutrient-rich environment while gnawing away at the very substrate that sustains them, all the while releasing inflammatory substances that cause pain—pain so severe that opioids ...

Fentanyl drives rise in opioid-linked deaths in U.S.

August 31, 2017
(HealthDay)—Fentanyl, a synthetic narcotic, is a key player in America's continuing epidemic of opioid-related overdose deaths, two new studies report.

Eating triggers endorphin release in the brain

August 28, 2017
Finnish researchers have revealed how eating stimulates brain's endogenous opioid system to signal pleasure and satiety.

Cholesterol-lowering drugs may fight infectious disease

August 21, 2017
That statin you've been taking to lower your risk of heart attack or stroke may one day pull double duty, providing protection against a whole host of infectious diseases, including typhoid fever, chlamydia, and malaria.

Data revealed under FOI shows benefits of multiple sclerosis drug currently blocked by regulators

August 17, 2017
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.